



an Open Access Journal by MDPI

New Challenges for Natural and Vaccine-Induced Immunity against HBV Infection

Guest Editors:

Dr. Romina Salpini

Department of Experimental Medicine, Tor Vergata University, 00133 Rome, Italy

Dr. Valentina Svicher

Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy

Dr. Olympia E Anastasiou

Institute of Virology, University Hospital Essen, Essen, Germany

Deadline for manuscript submissions: closed (30 June 2022)



Message from the Guest Editors

The availability of an effective vaccine against hepatitis B infection has produced a strong decline in the number of new cases of HBV-related hepatitis worldwide.

It is worth noting that, despite the overall high efficacy of anti-HBV vaccination, a non-negligible (but not well-defined) ratio of persons are "nonresponders" to the vaccine, failing to achieve a protective concentration of antibodies able to prevent HBV infection.

Another potential pitfall of HBV vaccination, and more generally of immune control of HBV, is related to the circulation of viral strains, carrying mutations in the surface antigen (HBsAg), that have been demonstrated to alter the affinity of antibodies, both naturally produced by the immune system and induced by vaccination.

For this Special Issue, we welcome all original research papers, reviews, clinical cases, and methodological novelties able to shed new light on the immune response to HBV infection, including that induced by anti-HBV vaccination, and on the role of HBV genetic variability in modifying the ability of the immune system and vaccination to prevent/control HBV infection.







an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office MDPI, St. Alban-Anlage 66 4052 Basel, Switzerland Tel: +41 61 683 77 34 www.mdpi.com mdpi.com/journal/vaccines vaccines@mdpi.com